Although LAG-3 blockade, along with IL-12 treatment, was shown to restore the anti-metastatic activity of NK cells in murine models of breast cancer, relatlimab did not directly induce NK cell-mediated cytotoxicity against leukemic cells. Here, LAG3 is linked to breast carcinoma.